Stepping up: simple test may revolutionize COPD rehab access

NCT ID NCT04008615

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 65 people with COPD to see if a simple six-minute stepper test can give similar information as a standard, more complex exercise test. The goal is to make it easier for patients to get assessed for pulmonary rehabilitation, especially in places where the standard test isn't available. Researchers measured oxygen use and other body responses during both tests to compare them.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

65 people

The number who actually took part.

Started

Aug 2019

Finished

Jun 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with chronicle obstructive pulmonary disease reffered for pulmonary rehabilitation.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age \> 18 ans ; * Chronicle obstructive pulmonary disease stage I/IV ; * Weight ≤ 90kg ; * Eligible for pulmonary rehabilitation. Exclusion Criteria: * Require during exercise oxygen ; * Pregnant woman or likely to be ; * Patient under guardianship ; * Contraindication to cardiopulmonary exercise testing ; * Patient medically treated with heart rate modulator (excluding oral B2-agonist) ; * Patient treated with pacemaker or defibrillator ; * History of lower limb impairment (i.e. peripheral artery disease, orthopedic disorder etc.).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for 6-minute stepper test are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • ADIR Association

    Bois-Guillaume, France

  • Centre Hostalier Intercommunal Elbeuf-Louviers-Val de Reuil

    Elbeuf, France

  • Groupe Hospitalier du Havre

    Le Havre, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.